EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC December 31, 2024
U.S. FDA Approves BRAFTOVI Combination Regimen as 1L Treatment of BRAF V600E-Mutant mCRC December 25, 2024
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer December 18, 2024
Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced December 18, 2024
FDA Clears IND Application for Ph 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic CRC December 4, 2024
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology November 26, 2024
Positive CHMP Opinion for Opdivo® (nivolumab) + Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with MSI-H or MRD Metastatic CRC November 19, 2024
FDA gives clearance to commence Ph 2 trial of leronlimab in patients with R/R MSS CRC November 13, 2024
Ph 1b Clinical Trial expanded to Evaluate TTX-080 in Combination with Cetuximab and Chemotherapy in Advanced Colorectal Cancer November 5, 2024
FDA clearance to commence Ph 2 trial of leronlimab in patients with R/R microsatellite stable CRC November 5, 2024
Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced October 8, 2024
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer October 2, 2024
FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC October 1, 2024
FRUZAQLA (fruquintinib) approved in Japan for the Treatment of Unresectable Advanced or Recurrent CRC October 1, 2024
FAILED TRIAL: CONTACT-02 Ph 3 mCRC trial did not meet statistical significance of OS endpoint September 17, 2024
FAILED TRIAL: Ph 2 NuTide:323 CRC Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee September 3, 2024
End-of-Phase-2 Meeting Outcomes and Topline Interim Ph 2 Data for BOT/BAL in MSS Colorectal Cancer announced July 23, 2024
Positive Initial Data Announced from Ph 1 MINOTAUR Trial of Lunresertib in Combination with FOLFIRI July 1, 2024
